Ming Bai

Ming Bai joined Flagship Pioneering in 2021 as Principal Scientist, Head of in vitro Pharmacology for Pioneering Medicines. He is responsible for advancing the laboratory capacity and leading a research team to conduct in vitro studies of efficacy, potency, mechanisms of action (MOA), and exploratory biology for Pioneering Medicines’ potential therapeutics, supporting the portfolio and pipeline development of innovative medicines.

Ming is a cell biologist and immunologist with a multidisciplinary background in biological research. Prior to joining Flagship, he was Senior Scientist in the Immuno-Oncology Therapeutic Area at Sanofi, where he was the in vitro pharmacology lead for different projects which involved a variety of modalities including one project that entered M2 stage and will go to first-in-human trial in 2022.

Before joining Sanofi, Ming was the group leader of in vitro pharmacology at QLB Biotherapeutics, a US subsidiary of Qilu Pharmaceutical (China). During his three years at QLB, Ming was a key contributor to multiple therapeutic antibody projects in Immuno-Oncology and Immunology indications, including mAbs and BsAb.

Prior to joining the biotech industry, Ming was Postdoctoral Fellow and then an instructor in the division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital/Harvard Medical School. While there he received extensive training in cell biology and immunology with a track record of publications including first-authorship in Nature Cell Biology and Blood and J Biol Chem. Ming received his Ph.D. in Biochemistry and Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.